Skip to main content

Evogene Ltd.

corporate_fare Company Profile

Evogene Ltd.

EVGN·NASDAQ·Industrial Applications And Services·CIK 0001574565

Evogene Ltd. is a computational biology company operating in Israel, the United States, Europe, and Africa. The company is structured into three segments: Agriculture, Human Health, and Industrial Applications. In its Agriculture segment, Evogene engages in activities related to seed traits and ag-chemicals. For Human Health, the company designs novel small molecules for drug development, utilizing its ChemPass AI, a computational generative AI engine. It also has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The Industrial Applications segment focuses on the development and commercialization of castor bean seeds for industrial uses. Additionally, the company is involved with medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.

Evogene Ltd. (NASDAQ:EVGN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek monitors EVGN SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Evogene CEO Outlines Strategic Pivot to AI-Driven Drug & Ag-Chemical Discovery
  • Evogene Secures $3.4M from Induced Warrant Exercise, Issues New Warrants
  • Evogene Subsidiary Biomica Licenses Cancer Therapeutic BMC128 to Lishan Biotech
  • Evogene CFO Yaron Eldad Resigns; VP Finance Polina Ravzin to Assume Role

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.85M
Net Income
-$7.83M
Diluted EPS
$1.08
Op. Cash Flow
-$13.5M
Free Cash Flow
-$13.64M
Gross Profit
-$241K
Operating Income
-$14.03M
Cash & Equivalents
$12.43M
Debt / Equity
0.00×
Net Margin
-203.1%
Shares Outstanding
8.72M sh
Source: 20-F · filed 2026-03-26 · accession 0001178913-26-001767

Insider Transactions

EVGN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$0.4801 -0.01% today
52-week range · as of 2026-07-27 $0.37 – $1.5
Market cap
$5.99M
Volume
77.3K (0.0× avg)
3-mo avg 2.6M
Live data · 2026-07-29 04:38 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed EVGN - Filings & News (Page 2)

EVGN
Feb 25, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Evogene CEO Outlines Strategic Pivot to AI-Driven Drug & Ag-Chemical Discovery
Price at Filing: $0.8383
Real-time Price: $0.4801 info
Change: -$0.3582 (-43%) info
Market Cap: $5.985M info
Sentiment: Positive
View Wiseek Article
EVGN
Feb 11, 2026, 4:00 PM EST
Filing Type: 6-K
Importance Score:
8
Evogene Secures $3.4M from Induced Warrant Exercise, Issues New Warrants
Price at Filing: $1.01
Real-time Price: $0.4801 info
Change: -$0.530 (-52%) info
Market Cap: $5.985M info
Sentiment: Neutral
View Wiseek Article
EVGN
Feb 04, 2026, 8:00 AM EST
Filing Type: 6-K
Importance Score:
8
Evogene Subsidiary Biomica Licenses Cancer Therapeutic BMC128 to Lishan Biotech
Price at Filing: $1.03
Real-time Price: $0.4801 info
Change: -$0.5499 (-53%) info
Market Cap: $5.985M info
Sentiment: Positive
View Wiseek Article
EVGN
Jan 15, 2026, 4:00 PM EST
Filing Type: 6-K
Importance Score:
7
Evogene CFO Yaron Eldad Resigns; VP Finance Polina Ravzin to Assume Role
Price at Filing: $1.06
Real-time Price: $0.4801 info
Change: -$0.5799 (-55%) info
Market Cap: $5.985M info
Sentiment: Neutral
View Wiseek Article